EUVIMEDEUVIMED entdecken
Crossref

Dexmedetomidine compared to low-dose ketamine better protected not only the brain but also the lungs in acute ischemic stroke

Luciana B B Heil, Cassia L Braga, Raquel F Magalhães, Mariana A Antunes, Fernanda F Cruz, Cynthia S Samary, Denise Battaglini, Chiara Robba, Paolo Pelosi, Pedro L Silva, Patricia R M Rocco

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.111004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Luciana B B Heil und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Ketamine, Dexmedetomidine, Ischemic Stroke, Stroke. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: CNPq, FAPERJ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dexmedetomidine (DEX) and low-dose ketamine (KET) present neuroprotective effects in acute ischemic stroke (AIS); however, to date, no studies have evaluated which has better protective effects not only on the brain but also lungs in AIS. METHODS: AIS-induced Wistar rats (390 ± 30 g) were randomized after 24-h, receiving dexmedetomidine (STROKE-DEX, n = 10) or low-dose S(+)-ketamine (STROKE-KET, n = 10). After 1-h protective ventilation, perilesional brain tissue and lungs were removed for histologic and molecular biology analysis. STROKE animals (n = 5), receiving sodium thiopental but not ventilated, had brain and lungs removed for molecular biology analysis. Effects of DEX and KET mean plasma concentrations on alveolar macrophages, neutrophils, and lung endothelial cells, extracted primarily 24-h after AIS, were evaluated. RESULTS: In perilesional brain tissue, apoptosis did not differ between groups. In STROKE-DEX, compared to STROKE-KET, tumor necrosis factor (TNF)-α and vascular cell adhesion molecule-1 (VCAM-1) expressions were reduced, but no changes in nuclear factor erythroid 2-related factor-2 (Nrf2) and super oxide dismutase (SOD)-1 were observed. In lungs, TNF-α and VCAM-1 were reduced, whereas Nrf2 and SOD-1 were increased in STROKE-DEX. In alveolar macrophages, TNF-α and inducible nitric oxide synthase (M1 macrophage phenotype) were lower and arginase and transforming growth factor-β (M2 macrophage phenotype) higher in STROKE-DEX. In lung neutrophils, CXC chemokine receptors (CXCR2 and CXCR4) were higher in STROKE-DEX. In lung endothelial cells, E-selectin and VCAM-1 were lower in STROKE-DEX. CONCLUSIONS: In the current AIS model, dexmedetomidine compared to low-dose ketamine reduced inflammation and endothelial cell damage in both brain and lung, suggesting greater protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineDexmedetomidineIschemic StrokeStrokeRatsAnimalsTumor Necrosis Factor-alphaNF-E2-Related Factor 2Endothelial CellsVascular Cell Adhesion Molecule-1Rats, WistarLungBrain

Stichwörter der Autor:innen

Brain-lung interactionDexmedetomidineFocal ischemic strokeInflammationKetamine

Substanzen

KetamineDexmedetomidineTumor Necrosis Factor-alphaNF-E2-Related Factor 2Vascular Cell Adhesion Molecule-1

Autor:innen und Institutionen

  • Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Rio de Janeiro Network on Neuroinflammation, Rio de Janeiro State Researc…
  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy; Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.

Förderung

  • CNPq
  • FAPERJ

Zitieren

APA

Heil, L. B. B., Braga, C. L., Magalhães, R. F., Antunes, M. A., Cruz, F. F., Samary, C. S., Battaglini, D., Robba, C., Pelosi, P., Silva, P. L., & Rocco, P. R. M. (2023). Dexmedetomidine compared to low-dose ketamine better protected not only the brain but also the lungs in acute ischemic stroke. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.111004

Vancouver

Heil LBB, Braga CL, Magalhães RF, Antunes MA, Cruz FF, Samary CS, et al. Dexmedetomidine compared to low-dose ketamine better protected not only the brain but also the lungs in acute ischemic stroke. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.111004

BibTeX
@article{Heil2023,
  author = {Heil, Luciana B B and Braga, Cassia L and Magalhães, Raquel F and Antunes, Mariana A and Cruz, Fernanda F and Samary, Cynthia S and Battaglini, Denise and Robba, Chiara and Pelosi, Paolo and Silva, Pedro L and Rocco, Patricia R M},
  title = {Dexmedetomidine compared to low-dose ketamine better protected not only the brain but also the lungs in acute ischemic stroke},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.111004}
}
Kostenlos starten →